Nalaganje...
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
AIMS/HYPOTHESIS: In addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 diabetes. METHODS: Changes from baseline alanine a...
Shranjeno v:
| izdano v: | Diabetologia |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Berlin Heidelberg
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6133166/ https://ncbi.nlm.nih.gov/pubmed/30066148 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-018-4702-3 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|